Amneal Pharmaceuticals (NYSE:AMRX) Price Target Lowered to $3.00 at Piper Sandler

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) had its price target decreased by Piper Sandler from $5.00 to $3.00 in a research report released on Monday, The Fly reports.

Several other research analysts also recently commented on the stock. Truist Financial decreased their price target on shares of Amneal Pharmaceuticals from $5.00 to $4.00 and set a buy rating on the stock in a research note on Wednesday, March 29th. The Goldman Sachs Group decreased their target price on shares of Amneal Pharmaceuticals from $3.50 to $3.00 and set a buy rating on the stock in a research note on Friday, March 3rd. Barclays decreased their target price on shares of Amneal Pharmaceuticals from $7.00 to $4.00 and set an overweight rating on the stock in a research note on Friday, March 10th. BMO Capital Markets decreased their target price on shares of Amneal Pharmaceuticals from $5.00 to $4.00 and set a market perform rating on the stock in a research note on Friday, March 3rd. Finally, StockNews.com began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, March 17th. They issued a hold rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average price target of $3.60.

Get Amneal Pharmaceuticals alerts:

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $2.02 on Monday. The firm has a 50 day moving average of $1.58 and a 200-day moving average of $2.04. The company has a current ratio of 1.88, a quick ratio of 1.17 and a debt-to-equity ratio of 14.30. Amneal Pharmaceuticals has a 12 month low of $1.24 and a 12 month high of $3.77. The firm has a market capitalization of $613.31 million, a P/E ratio of -2.24, a price-to-earnings-growth ratio of 0.18 and a beta of 1.33.

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) last announced its earnings results on Friday, May 5th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. The business had revenue of $557.54 million for the quarter, compared to the consensus estimate of $555.00 million. Amneal Pharmaceuticals had a negative net margin of 5.88% and a positive return on equity of 76.11%. During the same period last year, the firm posted $0.10 earnings per share. As a group, sell-side analysts predict that Amneal Pharmaceuticals will post 0.42 earnings per share for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AMRX. American Century Companies Inc. bought a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $30,000. Bank of Montreal Can bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $31,000. Engineers Gate Manager LP bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $34,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $35,000. Finally, Ergoteles LLC bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $36,000. Institutional investors own 32.79% of the company’s stock.

Amneal Pharmaceuticals Company Profile

(Get Rating)

Amneal Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals.

Recommended Stories

• Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
• Is the Electric Vehicle Movement Losing Steam?
• 3 High-Yield Banks Insiders Are Buying 
• Will ChatGPT Be the Final Nail in the Coffin for Chegg?
• Is the Market Reacting Too Negatively to Pinterest Earnings?
• More Analysts Should See Energizer Holdings As A Buy: Here Is Why

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.